Drug Insights © October 2015

Drug Pipeline Update

→ New Drug Information

• **Tresiba™ (insulin degludec) and Ryzodeg™ 70/30 (insulin degludec/insulin aspart):** Novo Nordisk received Food and Drug Administration (FDA) approval for two long-acting insulins for the treatment of diabetes. Insulin degludec was approved alone as Tresiba, and in combination with insulin as Ryzodeg. The insulins are both subcutaneously injected. Tresiba will compete against Lantus®, Levemir® and Toujeo®. Both drugs are anticipated to be launched in early 2016.

• **Aristada™ (aripiprazole lauroxil):** The FDA approved Alkermes’ Aristada for the treatment of schizophrenia. Aristada is administered by a health care professional every four to six weeks by intramuscular injection.

→ New Generics

• **Invega® (paliperidone ER):** Multiple manufacturers have launched their generic versions of Janssen's Invega extended-release tablets for the treatment of schizophrenia. According to IMS health, Invega had approximately $612 million in annual U.S. sales.

• **Lescol® XL (fluvastatin):** A generic version of Novartis' Lescol XL for high cholesterol is now available. According to IMS health, Lescol XL had approximately $38 million in annual U.S. sales.

• **Androgel® (testosterone transdermal gel, 1%):** A generic version of AbbVie’s transdermal testosterone gel, Androgel, has launched in the 1 percent strength. Other strengths are still available as brand only.

• **Orap® (pimozide):** Par has launched their generic version of Teva’s Orap, an antipsychotic indicated for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.

• **Testred® and Android® (methyltestosterone):** A generic version of Valeant’s Testred and Android is now available. Methyltestosterone is indicated as a hormone replacement in men/boys and for the treatment of metastatic breast cancer. According to IMS health, these products had approximately $14.5 million in annual U.S. sales.

• **Namenda® (memantine oral solution):** A generic version of Actavis’ Namenda oral solution is now available. Memantine tablets became available generically earlier in 2015.

• **Avodart® (dutasteride):** Teva has launched their generic version of GlaxoSmithKline’s Avodart for the treatment of benign prostatic hyperplasia (BPH) in men. Teva will hold marketing exclusivity for several weeks. According to IMS health, Avodart had approximately $467 million in annual U.S. sales.

While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. Each trademarked drug name is the property of its respective owner.